^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Tyvyt (sintilimab)

    i
    Other names: IBI308, IBI 308, IBI-308, LY-3342901
    Company:
    Eli Lilly, Innovent Biologics, Mankind Pharma
    Drug class:
    PD1 inhibitor
    Related drugs:
    1d
    EGFR-TKIs Plus PD-1 in EGFR-Mutant Advanced NSCLC (clinicaltrials.gov)
    P2, N=32, Recruiting, Nanfang Hospital, Southern Medical University
    New P2 trial • IO biomarker
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion
    |
    Tagrisso (osimertinib) • Tyvyt (sintilimab)
    2d
    Neoadjuvant sintilimab plus chemotherapy in EGFR-mutant non-small cell lung cancer (NEOTIDE/CTONG2104): phase II trial and correlative genomic analysis in China. (PubMed, EClinicalMedicine)
    Patients with resectable stage II-IIIB EGFR (AJCC 8th edition) mutant NSCLC were enroled and received neoadjuvant sintilimab (200 mg) plus carboplatin (area under the curve 5) and nab-paclitaxel (260 mg/m2) for 3 cycles. Patients in stage II cohort received adjuvant osimertinib for up to 2 years while observation for stage I cohort...provided PD-1 regimen (sintilimab), participant compensation and insurance. This work was supported by National Science Foundation of China, Noncommunicable Chronic Diseases-National Science and Technology Major Project, National Natural Science Foundation of China National High-Level Talents Special Support Program, National Natural Science Foundation of China Major Joint Project on Key scientific issues of lung Cancer, Guangdong Provincial Key Lab of Translational Medicine in Lung Cancer, Integrated Project of Major Research Plan of National Natural Science Foundation of China, National Health Commission Medical and Health Technology Development Research Centre Project.
    P2 data • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    RB1 (RB Transcriptional Corepressor 1) • RBM10 (RNA Binding Motif Protein 10)
    |
    EGFR mutation
    |
    Tagrisso (osimertinib) • carboplatin • Tyvyt (sintilimab) • albumin-bound paclitaxel • Tozaride (Rhenium (Re) 188 P2045)
    8d
    IBI343 in Combination With Sintilimab and SOX Regimen for Perioperative Treatment of Resectable, Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov)
    P2, N=90, Recruiting, Innovent Biologics (Suzhou) Co. Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    CLDN18 (Claudin 18)
    |
    CLDN18.2 expression
    |
    Tyvyt (sintilimab) • oxaliplatin • Teysuno (gimeracil/oteracil/tegafur) • arcotatug tavatecan (TAK-921)
    8d
    PACIFIC15: Effect of Time-of-Day (ToD) for Immunochemotherapy on PFS in NSCLC (clinicaltrials.gov)
    P3, N=210, Completed, Hunan Province Tumor Hospital | Recruiting --> Completed | Trial completion date: Dec 2025 --> Apr 2026
    Trial completion • Trial completion date
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    EGFR mutation
    |
    Keytruda (pembrolizumab) • Tyvyt (sintilimab)
    8d
    PRIME-PCNSL: A Multicenter, Prospective Clinical Trial With a Concurrent Control Evaluating Methotrexate Combined With Rituximab,Sintilimab and Pirtobrutinib vs. Investigator-Selected Standard of Care in Treatment-Naive PCNSL (clinicaltrials.gov)
    P2, N=77, Recruiting, Tongji Hospital | N=110 --> 77
    Enrollment change
    |
    Rituxan (rituximab) • Tyvyt (sintilimab) • temozolomide • cytarabine • Jaypirca (pirtobrutinib)
    8d
    Tafolecimab Combined With Sintilimab and SOX in the Treatment of pMMR/MSS Gastric Cancer (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, First Affiliated Hospital of Zhejiang University
    New P2 trial • pMMR
    |
    Tyvyt (sintilimab) • oxaliplatin
    9d
    DosinTACE: Donafenib Plus Sintilimab in Combination With TACE in Patients With Unresectable Hepatocellular Carcinoma (clinicaltrials.gov)
    P2, N=48, Active, not recruiting, Nanfang Hospital, Southern Medical University | Not yet recruiting --> Active, not recruiting | Trial primary completion date: Dec 2024 --> Mar 2026
    Enrollment closed • Trial primary completion date
    |
    Tyvyt (sintilimab) • Zepsun (donafenib)
    13d
    NeoShot: A Clinical Trial Evaluating the Efficacy and Safety of IBI310 in Combination With Sintilimab, for Neoadjuvant Treatment of MSI-H/dMMR Resectable Colon Cancer (clinicaltrials.gov)
    P3, N=453, Active, not recruiting, Innovent Biologics (Suzhou) Co. Ltd. | Recruiting --> Active, not recruiting
    Enrollment closed • Mismatch repair • MSI-H • dMMR
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    Tyvyt (sintilimab) • Tabosun (ipilimumab N01 injection)
    13d
    Study of IBI3005 Combination Therapy in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1/2, N=282, Not yet recruiting, Innovent Biologics (Suzhou) Co. Ltd.
    New P1/2 trial
    |
    ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    EGFR L858R • EGFR exon 19 deletion
    |
    Avastin (bevacizumab) • Tagrisso (osimertinib) • carboplatin • Tyvyt (sintilimab) • limertinib (ASK120067)
    15d
    RAPID: The Combination of Radiotherapy, Chemotherapy and Immunotherapy in High-Risk Localized Soft Tissue Sarcoma (clinicaltrials.gov)
    P1/2, N=52, Recruiting, Fudan University | Trial primary completion date: Aug 2024 --> Aug 2027
    Trial primary completion date
    |
    Tyvyt (sintilimab) • pegylated liposomal doxorubicin
    19d
    TACE Combined With Thermal Ablation and ADC, PD-1, and Chemotherapy as First-line Treatment for HER2-highly-expressing Gastric Cancer With Liver Metastases: A Multicenter, Single-arm Prospective Clinical Study. (clinicaltrials.gov)
    P2, N=40, Not yet recruiting, Shandong Provincial Hospital
    New P2 trial • Checkpoint inhibition
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
    |
    HER-2 overexpression • HER-2 expression
    |
    Tyvyt (sintilimab)
    19d
    Sintilimab Plus Chemotherapy as Induction Therapy for Unresectable Stage IIIC NSCLC (clinicaltrials.gov)
    P2, N=33, Not yet recruiting, Sun Yat-sen University
    New P2 trial
    |
    cisplatin • carboplatin • Tyvyt (sintilimab) • albumin-bound paclitaxel